Source link : https://newshealth.biz/health-news/dual-sglt1-2-inhibitor-protects-against-mi-and-stroke/
The dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor sotagliflozin reduced major adverse cardiovascular events, with significant reductions in the individual outcomes of myocardial infarction (MI) and stroke in patients with type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors in a prespecified secondary analysis of the SCORED trial. This ischemic benefit of […]
Author : News Health
Publish date : 2025-02-27 12:09:11
Copyright for syndicated content belongs to the linked Source.